We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+21.22%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$631M
AUM Growth
+$110M
Cap. Flow
+$37M
Cap. Flow %
5.86%
Top 10 Hldgs %
26.93%
Holding
113
New
5
Increased
44
Reduced
29
Closed
9

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$17M
2
GKOS icon
Glaukos
GKOS
+$9.15M
3
BIIB icon
Biogen
BIIB
+$9.05M
4
ELGX
Endologix Inc
ELGX
+$6.78M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.67M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$13.1M
2
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$11.1M
3
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$5.44M
4
BMY icon
Bristol-Myers Squibb
BMY
+$4.39M
5
CNC icon
Centene
CNC
+$4.18M

Sector Composition

Rank Sector Weight
1 Healthcare 92%
2 Financials 1.18%
3 Technology 0.15%
4 Energy 0.12%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMRX
76
DELISTED
Chimerix, Inc.
CMRX
$2.55M 0.4%
400,000
– –
CHRS icon
77
Coherus Oncology
CHRS
$196M
$2.35M 0.37%
111,357
– –
HALO icon
78
Halozyme
HALO
$12.2B
$2.2M 0.35%
170,000
-10,000
-6% -$126K
BIVV
79
DELISTED
Bioverativ Inc. Common Stock
BIVV
$1.69M 0.27%
+31,000
New +$1.53M
PODD icon
80
Insulet
PODD
$9.79B
$1.51M 0.24%
35,000
– –
RGLS
81
DELISTED
Regulus Therapeutics
RGLS
$979K 0.16%
4,947
+1,046
+27% +$199K
BDX icon
82
Becton Dickinson
BDX
$48.2B
$917K 0.15%
5,125
– –
TSRO
83
DELISTED
TESARO, Inc.
TSRO
$769K 0.12%
5,000
-15,000
-75% -$2.44M
ACHN
84
DELISTED
Achillion Pharmaceuticals
ACHN
$699K 0.11%
166,000
– –
CNCE
85
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$513K 0.08%
30,099
– –
ATXS
86
DELISTED
Astria Therapeutics
ATXS
$497K 0.08%
5,179
+3,512
+211% +$484K
JPM icon
87
JPMorgan Chase
JPM
$950B
$425K 0.07%
4,837
+750
+18% +$66.2K
ADVM
88
DELISTED
Adverum Biotechnologies
ADVM
$416K 0.07%
15,401
– –
OREX
89
DELISTED
Orexigen Therapeutics, Inc.
OREX
$413K 0.07%
120,000
– –
WFC icon
90
Wells Fargo
WFC
$264B
$407K 0.06%
7,305
+1,187
+19% +$67.3K
XOM icon
91
ExxonMobil
XOM
$634B
$396K 0.06%
4,823
+1,628
+51% +$136K
HAL icon
92
Halliburton
HAL
$26.6B
$380K 0.06%
7,718
+2,787
+57% +$150K
OCUL icon
93
Ocular Therapeutix
OCUL
$2.02B
$371K 0.06%
40,000
– –
MSFT icon
94
Microsoft
MSFT
$3.71T
$316K 0.05%
4,793
– –
BUD icon
95
AB InBev
BUD
$165B
$308K 0.05%
2,806
+626
+29% +$67.3K
IBM icon
96
IBM
IBM
$224B
$308K 0.05%
1,847
– –
QCOM icon
97
Qualcomm
QCOM
$176B
$308K 0.05%
5,368
+1,242
+30% +$72.1K
STAA icon
98
STAAR Surgical
STAA
$1.21B
$281K 0.04%
28,711
– –
TNDM icon
99
Tandem Diabetes Care
TNDM
$1.56B
$281K 0.04%
23,400
– –
F icon
100
Ford
F
$55.7B
$262K 0.04%
22,511
– –
1 2 3
4
5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2017 Portfolio in Review

As of Q1 2017, Rhenman & Partners Asset Management held 113 positions worth $631M, up 21% from $522M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rhenman & Partners Asset Management deployed $37M of net new capital in Q1 2017, opening 5 new positions and adding to 44 existing holdings. Its largest new stake was Abbott: 115,000 shares worth $5.11M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 95% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $4.39M trimmed.

  • Rhenman & Partners Asset Management's largest Q1 2017 buy was Abbott: 115,000 shares worth $5.11M.
  • Rhenman & Partners Asset Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2017, an estimated $17M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2017 reduction was Bristol-Myers Squibb, cutting an estimated $4.39M.
  • Rhenman & Partners Asset Management fully exited Teva Pharmaceuticals in Q1 2017, selling an estimated $13.1M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 27% of its $631M portfolio in Q1 2017.
  • Rhenman & Partners Asset Management opened 5 new positions and closed 9 in Q1 2017.
  • Rhenman & Partners Asset Management's portfolio value rose 21% quarter-over-quarter to $631M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2017, filed 19 Apr 2017.